146 related articles for article (PubMed ID: 26415895)
1. Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.
Martin AP; Richards S; Haycox A; Houten R; McLeod C; Braithwaite B; Clark JO; Bell J; Clark RE
J Clin Apher; 2016 Oct; 31(5):434-42. PubMed ID: 26415895
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
Tichopád A; Vítová V; Kořístek Z; Lysák D
J Clin Apher; 2013 Dec; 28(6):395-403. PubMed ID: 23922227
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients.
Clark RE; Bell J; Clark JO; Braithwaite B; Vithanarachchi U; McGinnity N; Callaghan T; Francis S; Salim R
Blood Cancer J; 2014 Oct; 4(10):e255. PubMed ID: 25360901
[TBL] [Abstract][Full Text] [Related]
4. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
[TBL] [Abstract][Full Text] [Related]
5. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
Costa LJ; Kramer C; Hogan KR; Butcher CD; Littleton AL; Shoptaw KB; Kang Y; Stuart RK
Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly.
Hay AE; Lawrie A; Robinson N; Dong B; Culligan DJ
J Clin Apher; 2013 Oct; 28(5):378-80. PubMed ID: 23483573
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
Milone G; Martino M; Spadaro A; Leotta S; Di Marco A; Scalzulli P; Cupri A; Di Martina V; Schinocca E; Spina E; Tripepi G
Br J Haematol; 2014 Jan; 164(1):113-23. PubMed ID: 24138497
[TBL] [Abstract][Full Text] [Related]
8. G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.
Antar A; Otrock ZK; Kharfan-Dabaja MA; Ghaddara HA; Kreidieh N; Mahfouz R; Bazarbachi A
Bone Marrow Transplant; 2015 Jun; 50(6):813-7. PubMed ID: 25751646
[TBL] [Abstract][Full Text] [Related]
9. GCSF with or without chemotherapy compared to Plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: collection effectiveness and cost effectiveness analysis.
Abdel-Rahman F; Tuffaha HW; Sharma S; Jazar HA; Hussein N; Saad A; Al Rawi O; Hussein A
J Oncol Pharm Pract; 2014 Apr; 20(2):130-6. PubMed ID: 23676506
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
Costa LJ; Alexander ET; Hogan KR; Schaub C; Fouts TV; Stuart RK
Bone Marrow Transplant; 2011 Jan; 46(1):64-9. PubMed ID: 20383210
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
17. Plerixafor use in New Zealand 2016-2019: an observational study.
Swinn T; Butler A
Intern Med J; 2023 Jun; 53(6):970-977. PubMed ID: 35560504
[TBL] [Abstract][Full Text] [Related]
18. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
[TBL] [Abstract][Full Text] [Related]
19. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.
Douglas KW; Parker AN; Hayden PJ; Rahemtulla A; D'Addio A; Lemoli RM; Rao K; Maris M; Pagliuca A; Uberti J; Scheid C; Noppeney R; Cook G; Bokhari SW; Worel N; Mikala G; Masszi T; Taylor R; Treisman J
Bone Marrow Transplant; 2012 Jan; 47(1):18-23. PubMed ID: 21358693
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C; Waller EK
Transfusion; 2015 Oct; 55(10):2351-7. PubMed ID: 26331348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
